ProjectDAPT Substudie – National Biomarker / Platelet Function sub-study of DAPT-SHOCK Trial
Basic data
Acronym:
DAPT Substudie
Title:
National Biomarker / Platelet Function sub-study of DAPT-SHOCK Trial
Duration:
23/12/2021 to 31/12/2023
Abstract / short description:
To evaluate the effect of cangrelor + ticagrelor versus placebo + ticagrelor on biomarker expression and platelet function in cardiogenic shock patients undergoing PCI:
Inhibition of platelet function at the end of PCI as measured by agonist induced platelet aggregation at the end of PCI.
Course of platelet function, platelet reactivity as measured by various platelet activation markers and monocyte activation measured by flow cytometry over time.
Biomarker analysis of soluble platelet dependent and systemic inflammatory markers (e.g. Interleukin 1/6, CD40L, TNF alpha, VEGF, HMGB1)
1:1 Comparison between patients randomized to cangrelor versus placebo
Inhibition of platelet function at the end of PCI as measured by agonist induced platelet aggregation at the end of PCI.
Course of platelet function, platelet reactivity as measured by various platelet activation markers and monocyte activation measured by flow cytometry over time.
Biomarker analysis of soluble platelet dependent and systemic inflammatory markers (e.g. Interleukin 1/6, CD40L, TNF alpha, VEGF, HMGB1)
1:1 Comparison between patients randomized to cangrelor versus placebo
Involved staff
Managers
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Faculty of Medicine
University of Tübingen
University of Tübingen
Other staff
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Herzogenrath, Nordrhein-Westfalen, Germany